Global Cell Therapy Market, Clinical Trials, Therapy Price and Opportunity Insight 2026

For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990

Download Report: https://www.kuickresearch.com/report-global-cell-therapy-market,-clinical-trials,-therapy-price-and-opportunity-insight-2026.php

Report Table of Contents

1. Overview of Cell Therapy
1.1 Introduction to Cell Therapy
1.2 History and Evolution of Cell Therapy

2. Types of Cell Therapy
2.1 Allogeneic Cell Therapy
2.2 Autologous Cell Therapy
2.3 Human Embryonic Stem Cell Therapy
2.4 Neural Stem Cell Therapy
2.5 Mesenchymal Stem Cell Therapy
2.6 Hematopoietic Stem Cell Transplantation

3. Mechanism of Therapeutic Action in Cell Therapy

4. Manufacturing of Cell Therapies
4.1 Models for Manufacturing Cell Therapies
4.2 Facilities for Good Manufacturing Practice

5. Advantages of Cell Therapy Over Conventional Therapy
5.1 Anti-Aging with Cell Therapy
5.2 Addressing Other Diseases with Cell Therapy

6. Personalized Cell Therapy
6.1 Overview of Personalized Cell Therapy
6.2 Personalized Cell Therapy Using Epigenetic Tools
6.3 Personalized Cell Therapy through Mesenchymal Stem Cells
6.4 Treatment of Parkinson’s Disease through IPSCs
6.5 Case Study: Personalized Cell Therapy for Pulpitis Using Autologous Dental Pulp Stem Cells and Leukocyte Platelet Rich Fibrin

7. Cell Therapy Application by Therapeutic Areas
7.1 Cardiovascular Disease
7.2 Neurological Disorders
7.3 Inflammatory Diseases
7.4 Diabetes
7.5 Cancer

8. Global Cell Therapy Market Outlook
8.1 Current Market Scenario
8.2 Cell Therapy Market by Cell Source
8.2.1 Induced Pluripotent Stem Cell (IPSCs)
8.2.2 Bone Marrow
8.2.3 Umbilical Cord Blood Derived Cells
8.3 Global Cell Therapy Clinical Pipeline (Company,Indication, Region) Overview

9. US - Cell Therapy Dosage and Cost Analysis
9.1 Allocord
9.2 Laviv
9.3 Maci
9.4 Clevecord
9.5 Hemacord
9.6 Ducord
9.7 Provenge
9.8 HPC, Cord Blood (Clinimmune Labs, University of Colorado Cord Blood Bank)
9.9 HPC, Cord Blood (LifeSouth Community Blood Centers, Inc)
9.10 HPC, Cord Blood (Bloodworks)
9.11 HPC, Cord Blood (MD Anderson Cord Blood Bank)
9.12 Gintuit
9.13 Kymriah*
9.14 Yescarta*
9.15 Carticel

10. South Korea - Cell Therapy Dosage and Cost Analysis
10.1 Cartistem
10.2 Chondron
10.3 KeraHeal
10.4 Cellgram
10.5 Cure Skin Injection

11. Australia, Europe and Japan - Cell Therapy Dosage and Cost Analysis
11.1 Holoclar (Europe)
11.2 Yescarta (EU)
11.3 Kymriah (EU)
11.4 Temcell HS (Japan)
11.5 Chondrocytes-T-Ortho-ACI (Australia)

12. Cell Therapy Market Trends: Geographically
12.1 US
12.2 South Korea
12.3 Europe
12.4 Japan
12.5 China
12.6 Rest of the World
12.6.1 Africa
12.6.2 Middle East
12.6.3 South America

13. Advancements in Cell Therapy
13.1 Drug Based Therapies Advancements in Chronic Lymphocytic Leukemia
13.2 Advances in Cytomegalovirus Infection Prevention and Treatment
13.3 Stem Cell Therapy for the Treatment of Parkinson’s Disease
13.4 Stem Cell Therapy for the Treatment of Alzheimer’s Disease
13.5 Treatment of Rheumatoid Arthritis via Stem Cell Therapy
13.6 Role of Stem Cell Therapy in Treating Infertility
13.7 Stem Cells for Eye Diseases
13.8 Cell Therapy for Stroke and Angina Pectoris
13.9 Stem Cell Therapy in Improving Wrinkles and Acne Scars

14. Treg Cells andndash; The Next Edge of Cell Therapy
14.1 Introduction to Treg Cell
14.2 Isolation and Expansion of Treg Cell
14.3 Mechanism of Action
14.4 Clinical Trials of Treg Cell Therapy
14.4.1 Adoptive Cell Therapy of Treg cells to Prevent GvHD
14.4.2 Adoptive Cell Therapy of Polyclonal and Alloantigen-specific Treg cells to Prevent Solid Organ Transplant Rejection
14.5 Treg Cell Therapy for the Treatmet of Autoinflammatory and Autoimmune Diseases
14.5.1 Inflammatory Bowel Disease
14.5.2 Systemic Lupus Erythematosus
14.5.3 Autoimmune Hepatitis
14.5.4 Pemphigus Vulgaris
14.5.5 Allergy and Asthma
14.6 Future Prospects of Treg Cell Therapy

15. Global Cell Therapy Market Future Prospects

16. Marketed Cell Therapies Clinical Insight by Company and Indication
16.1 Tisagenlecleucel (Kymriah)
16.2 Axicabtagene Ciloleucel (Yescarta)
16.3 Allogeneic Cultured Keratinocytes And Fibroblasts (Gintuit)
16.4 Adipose Stem Cell Therapy (Adipocell (Anterogen), Cupistem and Queencell)
16.5 Tonogenchoncel-L (INVOSSA-K inj)
16.6 Mesenchymal Stem Cell Therapies (Stempeucel)
16.7 Remestemcel-L (Prochymal and TEMCELL HS Inj.)
16.8 Sipuleucel-T (Provenge)
16.9 Autologous Mesenchymal Stem Cell Therapy - Pharmicell
16.10 Autologous Cultured Chondrocytes (MACI)
16.11 Autologous Cultured Chondrocytes (Chondrotransplant DISC)
16.12 Autologous Corneal Epithelial Stem Cell Therapy (Holoclar)
16.13 Nalotimagene Carmaleucel (Zalmoxis)
16.14 Mesenchymal Stem Cell Therapy For Cartilage Repair (Cartistem)
16.15 Autologous Chondrocyte Implant - TETEC
16.16 Muscle-Derived Autologous Stem Cell Therapy (MyoCell)
16.17 Human Skin Replacement (CellSpray)
16.18 Leukocyte Cell Therapy (CureXcell)
16.19 Autologous Cultured Chondrocyte Implant (Carticel)
16.20 Azficel-T (Laviv)
16.21 Autologous Cultured Chondrocytes (CHONDRON)
16.22 Autologous Chondrocytes (BioCart)
16.23 Amniotic Cell Therapy (NuCel)
16.24 Dendritic Cell-Activated Cytokine-Induced Killer Cells - Shanghai Jia Fu Medical
16.25 Autologous Cultured Myoblasts And Fibroblasts (Urocell)

17. Global Cell Therapy Clinical Pipeline by Company, Indication and Phase
17.1 Research
17.2 Preclinical
17.3 Clinical
17.4 Phase-0
17.5 Phase-I
17.6 Phase-I/II
17.7 Phase-II
17.8 Phase-II/III
17.9 Phase-III
17.10 Preregistration
17.11 Registered

18. Competitive Landscape
18.1 Athersys Inc.
18.2 Baxter Healthcare Corporation
18.3 Bone Therapeutics
18.4 Celgene Corporation
18.5 Cell Medica
18.6 Cellerant Therapeutics
18.7 FibrocellScinence
18.8 Genzyme Corporation
18.9 Green Cross Cell
18.10 Histogenics Corporation
18.11 Intrexon Corporation
18.12 Intercytex
18.13 ISTO Biologics
18.14 Macrocure
18.15 Mesoblast
18.16 Molmed
18.17 Nuo Therapeutics Inc
18.18 OmniCyte
18.19 Opexa Therapeutics
18.20 Organogenesis
18.21 Pharmicell
18.22 TCA Cellular Therapy
18.23 Stem Cell Inc.
18.24 Teva Pharmaceuticals
18.25 Tigenix
18.26 Vericel Corporation

Figure 1-1: Cell Therapy Pathway
Figure 1-2: Evolution of Cell Therapy
Figure 2-1: Types of Cell Therapy
Figure 2-2: Steps in Allogeneic Cell Therapy
Figure 2-3: Steps in Autologous Cell Therapy
Figure 2-4: Steps in the Derivation of Human Embryonic Stem Cells
Figure 2-5: Cardinal Neural Stem Cell Properties
Figure 2-6: Mesenchymal Stem Cells Therapy Process
Figure 3-1: Cell Therapy Mechanism
Figure 4-1: Centralized Manufacturing Model
Figure 4-2: Near Patient Manufacturing Model
Figure 5-1: Major Steps in Cell Therapy
Figure 5-2: Global- Expected Aging Population of 60+ (Billion), 2015 and 2050
Figure 5-3: Advantages of Cell Therapy as a Rejuvenation Therapy
Figure 6-1: Advantages of Personalized Cell Therapy
Figure 6-2: Mesenchymal Stem Cells (MSCs) in Autism Spectrum Disorder (ASD) Treatment
Figure 6-3: Steps of iPSC Transplantation
Figure 7-1: Global - Mortality Caused by Non Communicable Disease (%), 2018
Figure 7-2: Cell Therapy for Cardiovascular Disease
Figure 7-3: Overview of Stem Cell Therapy in Cardiovascular Disease
Figure 7-4: Cell Therapy in Neurological Disorders
Figure 7-5: Cell Therapy in Treatment of Alzheimer's disease
Figure 7-6: Cell Therapy in Diabetes
Figure 8-1: Cell Therapy- The Final Therapeutic Pillar of Healthcare
Figure 8-2: Global - Cell Therapy Market (US$ Billion), 2018 - 2026
Figure 8-3: Process for Conventional Drug Delivery
Figure 8-4: Process for Induced Pluripotent Stem Cell Based Drug Delivery
Figure 8-5: Global- Induced Pluripotent Stem Cell Therapy Market (US$ Million), 2018 - 2026
Figure 8-6: Steps involved in Bone Marrow Transplant
Figure 8-7: Global - Cell Therapies Clinical Pipeline by Phase (%), 2019 till 2026
Figure 8-8: Global - Cell Therapies Clinical Pipeline by Phase (Number), 2019 till 2026
Figure 8-9: Global - Cell Therapies Clinical Pipeline by Region (Number), 2019 till 2026
Figure 8-10: Global - Cell Therapies Clinical Pipeline by Region (Number), 2019 till 2026
Figure 8-11: Global - Cell Therapies Clinical Pipeline by Company (Number), 2019
Figure 8-12: Global - Cell Therapies Clinical Pipeline by Indication (Number), 2019
Figure 9-1: US andndash; Allocord Infusion per Hour (Millilitres), Adult and Children
Figure 9-2: US andndash; Laviv Average Injection Cost of Initial and Whole Session (US$), March’2019
Figure 9-3: US andndash; Maci Cost Comparision over Mosaicplasty and Microfracture (US$)
Figure 9-4: US andndash; Clevecord Dosage of Nucleated Cells per Killogram (Million) and Average Cost (US$)
Figure 9-5: US andndash; Provenge Cost of Single Infusion vs Overall Cost (US$), July 2017
Figure 9-6: US andndash; Kymriah Average Dosage of CAR positive viable T cells (Paediatric and Adults), August 2017
Figure 9-7: US andndash; Kymriah Treatment Cost for Leukemia and Lymphomas (US$), July 2018
Figure 9-8: US andndash; Yescarta Target Dose vs Maximum Dose of CAR-positive viable T cells, October 2017
Figure 9-9: US - Yescarta and Kymriah Overall Treatment Cost (US$), April 2018
Figure 9-10: US - Yescarta and Kymriah Estimated Payment Rate by Centers for Medicare and Medicaid Services (US$), April, 2018
Figure 9-11: US andndash; Carticel Minimum and Maximum Cost (US$), October 2017
Figure 10-1: South Korea andndash; Cartistem Dosage (Microlitres per cm2) and Cost (US$), October 2017
Figure 10-2: South Korea andndash; Chondron Dosage (Millilitres per Vial) and Cost (US$), March 2019
Figure 10-3: South Korea - KeraHeal vs KeraHeal-Allo Dosage form (Miililitres Cell Suspension)
Figure 10-4: South Korea andndash; Cellgram Dosage (Cells per 10 Millilitre) and Cost (US$), October 2017
Figure 11-1: Europe andndash; Holoclar Minimum and Maximum Dosage (Cells per cm2) and Cost (US$), August’ 2017
Figure 11-2: European Union andndash; Yescarta Dosage of CAR-positive viable T cells by Body Weight
Figure 11-3: European Union - Yescarta and Kymriah Treatment Cost for acute lymphoblastic leukaemia and diffuse large B-cell lymphoma (US$), August’ 2018
Figure 11-4: Japan - Temcell Dosage of Cells per Killogram Body Weight (Million)
Figure 11-5: Japan andndash; Temcell Total Cost vs Cost per Bag (US$), October’ 2017
Figure 11-6: Australia - Ortho-ACI Constituents of Dulbecco’s Modified Eagle Medium (DMEM) nutrient mixture
Figure 11-7: Australia - Ortho-ACI Average Dose (Million Cells) and Cost of Treatment (US$)
Figure 12-1: Significance of Cell Therapy Market Technology
Figure 12-2: Drivers for Growth of Cell Therapy in Japan
Figure 12-3: Criteria Impacting Successful Cell Therapy
Figure 12-4: China Cell Therapy Market Strategy
Figure 12-5: Rest of the World andndash; Cell Therapy Clinical Trial by Region (%), 2019
Figure 13-1: Signaling Pathway in Chronic Lymphocytic Leukemia
Figure 13-2: Advantages of Treating Rheumatoid arthritis with Umbilical Cord Mesenchymal Stem Cells
Figure 13-3: Stem Cell Therapy for the Treatment of Male Infertility
Figure 13-4: Cell Therapy for Ptients with Angina
Figure 13-5: Benefits of Stem Cell Therapy in Aesthetic Purposes
Figure 14-1: Working of CD4+ and CD25+ Regulatory T-Cell
Figure 14-2: Mechanism of Action of Treg Cell
Figure 14-3: Therapeutic Action of Treg Cell
Figure 14-4: Future Applications of Treg Cells
Figure 15-1: Growth Opportunities for Cell Therapy
Figure 18-1: Bone Therapeutics Clinical Pipeline
Figure 18-2: Celgene Clinical Pipeline
Figure 18-3: Cell Medica Therapeutics Clinical Pipeline
Figure 18-4: Cellerant Therapeutics Clinical Pipeline
Figure 18-5: Fibrocell Science Clinical Pipeline
Figure 18-6: Intrexon Clinical Pipeline
Figure 18-7: Mesoblast Clinical Pipeline
Figure 18-8: Molmed Clinical Pipeline
Figure 18-9: Tigenix Clinical Pipeline
Figure 18-10: Vericel Corporation Clinical Pipeline






Table 2-1: Difference between Allogeneic and Autologous Cell Therapy
Table 5-1: Difference between Cell Therapy and Conventional Therapy
Table 13-1: Targeted Therapy in Patients with Chronic Lymphocytic Leukemia
Table 13-2: Targeted Therapy in Patients with Chronic Lymphocytic Leukemia
Table 13-3: Results of Phase I-II Trials of Adoptive Cell Therapy for Cytomegalovirus Infection in Allogeneic Hematopoietic Stem Cell Transplant
Table 14-1: Functions of Effector T-Cell and Treg Cell

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
New Delhi – 110 001, India
+91-11-47067990

This release was published on openPR.